Efficacy, Safety, and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older

Trial Profile

Efficacy, Safety, and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster; Varicella zoster virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ZOE-50; ZOSTER-006
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Sep 2017 According to a GlaxoSmithKline media release, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted unanimously that the data support the efficacy and safety of Shingrix, for the prevention of herpes zoster (shingles) in adults ages 50 and over. FDA Advisory Committees provide non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA.
    • 21 Jun 2017 According to a GlaxoSmithKline media release, data from this study were presented at the US Centers for Disease Control and Preventions Advisory Committee on Immunization Practices (ACIP) meeting.
    • 18 Apr 2017 According to a GlaxoSmithKline media release, the compnay has submitted a New Drug Application (NDA) in Japan seeking approval for the candidate shingles vaccine, Shingrix, for the prevention of herpes zoster (shingles) in people aged 50 years or over. The application included data from ZOE-50 and ZOE-70 studies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top